Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.

ABSTRACT:

Background and objectives

Vitamin D receptor activators and calcimimetics (calcium-sensing receptor agonists) are two major options for medical treatment of secondary hyperparathyroidism. A higher serum calcification propensity (a shorter T₅₀ value) is a novel surrogate marker of calcification stress and mortality in patients with CKD. We tested a hypothesis that a calcimimetic agent etelcalcetide is more effective in increasing T₅₀ value than a vitamin D receptor activator maxacalcitol.

Design, setting, participants, & measurements

A randomized, multicenter, open-label, blinded end point trial with active control was conducted in patients with secondary hyperparathyroidism undergoing hemodialysis in Japan. Patients were randomly assigned to receive int

SUBMITTER: Shoji T 

PROVIDER: S-EPMC8092049 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature